# Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

> **NCT03852433** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 175 (actual)

## Conditions studied

- Chronic Hepatitis Delta

## Interventions

- **DRUG:** Bulevirtide
- **DRUG:** Peginterferon Alfa-2a (PEG-IFN alfa)

## Key facts

- **NCT ID:** NCT03852433
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-31
- **Primary completion:** 2022-04-05
- **Final completion:** 2022-09-28
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03852433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03852433, "Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03852433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*